199 related articles for article (PubMed ID: 27760600)
21. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Duan JC; An TT; Wu MN; Yang L; Bai H; Wang ZJ; Wang YY; Zhuo ML; Zhao J; Wang SH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):323-8. PubMed ID: 22883988
[TBL] [Abstract][Full Text] [Related]
24. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.
Maeda C; Shinada K; Murakami S; Saito H
Thorac Cancer; 2023 Oct; 14(28):2886-2889. PubMed ID: 37641467
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Liu Y; Zhang Y; Zhang L; Liu B; Wang Y; Zhou X; Li Y; Zhao Q; Gong Y; Zhou L; Zhu J; Ding Z; Wang J; Peng F; Huang M; Li L; Ren L; Lu Y
Oncotarget; 2017 Jul; 8(30):49680-49688. PubMed ID: 28591695
[TBL] [Abstract][Full Text] [Related]
27. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
30. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
31. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
32. Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.
Shen X; Shen J; Zhang H; Cheng Y; Yang Y; Gao J; Zhang Y; Li R; Liu B; Wang L
Thorac Cancer; 2018 Jan; 9(1):181-184. PubMed ID: 29143497
[TBL] [Abstract][Full Text] [Related]
33. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib for the treatment of patients with
Alsharedi M; Bukamur H; Elhamdani A
Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
[TBL] [Abstract][Full Text] [Related]
35. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?].
Liu X; Xu J
Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):709-14. PubMed ID: 25342036
[TBL] [Abstract][Full Text] [Related]
37. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
38. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
[TBL] [Abstract][Full Text] [Related]
39. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
[TBL] [Abstract][Full Text] [Related]
40. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
